In clinical trials3,4,5Evidence: Large human trialsGut and digestion

Larazotide3

Also called Larazotide acetate3

Key takeaway

Larazotide is a synthetic eight-amino-acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly), recorded in FDA’s substance registry and also known as AT-1001 in its acetate form.3 It was developed for celiac disease. In a randomized, placebo-controlled trial of 342 adults with ongoing symptoms despite a gluten-free diet, the lowest of three strengths tested reduced symptoms more than placebo; the two higher strengths did not.4 No FDA approval is reported in the sources reviewed here. Larazotide does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.3,5,7

Larazotide at a glance

What it isA synthetic octapeptide, glycylglycyl-valyl-leucyl-valyl-glutaminyl-prolyl-glycine, according to FDA’s substance registry.3
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list larazotide.3,5
Human evidenceRandomized, placebo-controlled trials in celiac disease, including one of 342 adults published in 2015, with mixed results.4
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is larazotide?

Larazotide is a synthetic peptide of eight amino acids. FDA’s substance registry records it as larazotide and, as the acetate salt, as larazotide acetate and AT-1001.3

How is larazotide thought to work?

The 2015 trial authors describe it as a novel agent targeting the regulation of tight junctions, the seals between cells lining the gut.4

What do human studies show?

In a multicenter, randomized, double-blind trial published in 2015, 342 adults with celiac disease who still had symptoms after at least a year on a gluten-free diet received one of three strengths of larazotide or placebo for 12 weeks.4

The lowest strength met the main goal of fewer gastrointestinal symptoms than placebo, while the two higher strengths were no different from placebo on any outcome. Safety was comparable with placebo, and the authors described the results as mixed.4

ClinicalTrials.gov lists the 2015 trial (NCT01396213) as completed, and a Phase 2 trial in long COVID (NCT05747534) as completed in its August 18, 2026 record, which does not report findings.1,2

What the evidence base contains

  • Large randomized human trial A randomized, double-blind, placebo-controlled Phase 2 trial in 342 adults with celiac disease and persistent symptoms on a gluten-free diet (2015).4

Evidence-strength label: Large randomized human trials. How this label is assigned

Is larazotide FDA-approved?

None of the sources reviewed here reports an approval of larazotide by FDA.3,5

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list larazotide.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Larazotide is not among them.6,7

Timeline

  1. A randomized trial of larazotide in 342 adults with celiac disease is published.4
  2. FDA’s compounding safety-risk page is last updated; it does not list larazotide.5

What is still unknown?

Why only the lowest strength helped in the 2015 trial, and whether that benefit would hold in larger trials.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Larazotide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Larazotide are a bounded selection, not every registration or paper about Larazotide. For the years before Larazotide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Larazotide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Larazotide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; studied in clinical trials. In a randomized trial of 342 adults, only the lowest strength reduced celiac symptoms more than placebo. Larazotide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Larazotide?

Not FDA-approved; studied in clinical trials. In a randomized trial of 342 adults, only the lowest strength reduced celiac symptoms more than placebo. Larazotide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
5
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Clinical trials · added November 16, 2026

    ClinicalTrials.gov record NCT05747534↗Source date August 18, 2026
  2. Literature metadata · added November 16, 2026

    Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.↗Source date August 12, 2026
  3. Literature metadata · added November 16, 2026

    Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.↗Source date March 17, 2022

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Larazotide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

13Selected dated records
18Connected citations
5Populated source years2017–2026
2/4Record lanes present

Registered human studies

Trial composition

8 of 8 selected trial records include at least one phase value; 8 of 8 include a status value in the retained structured contract.

PhasesPhase 2 6Phase 1 2
Status at observationCompleted 8

PubMed bibliography

Publication composition

5 of 5 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 5Comment 2Clinical Trial, Phase II 1Randomized Controlled Trial 1Research Support, N.I.H., Extramural 1Research Support, Non-U.S. Gov't 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
13

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 13 dated records

Research hub

Explore the Larazotide evidence record

Open all 13 records →
13Dated records
2Evidence types
13Cited public sources
5Source years

Change ledger

Recently changed for Larazotide

Open all 13 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00362856

PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.

PeptideScanner change date
November 16, 2026
Cited source date
September 12, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00386165

PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide.

PeptideScanner change date
November 16, 2026
Cited source date
September 11, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00386490

PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.

PeptideScanner change date
November 16, 2026
Cited source date
September 12, 2017
Evidence lane
Clinical trials

Official-source collections

Source records for Larazotide

Open the full research atlas →
PubMed5

5 with attributed title, venue, publication-date, and type metadata.

  1. Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.Science translational medicine · 2025 07 30
  2. Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.Critical care explorations · 2022 02 18
  3. [Larazotide as an option in case of failure of a gluten-free diet].Medizinische Monatsschrift fur Pharmazeuten · 2016 Feb
Explore all selected literature →
ClinicalTrials.gov8

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05747534Registry update August 18, 2026 · completed at observation
  2. NCT00492960Registry update September 20, 2017 · completed at observation
  3. NCT00620451Registry update September 20, 2017 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span September 11, 2017 to August 18, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration3,5
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 13

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT05747534↗

    PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide.↗

  2. Literature metadata

    Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.↗

    PubMed lists PMID 40737433 in Science translational medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-30 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.↗

    PubMed lists PMID 35211683 in Critical care explorations as Journal Article, with publication-date metadata of 2022-02-18 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    [Larazotide as an option in case of failure of a gluten-free diet].↗

    PubMed lists PMID 26983338 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2016-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Commentary: larazotide acetate - an exciting new development for coeliac patients?↗

    PubMed lists PMID 23336683 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply.↗

    PubMed lists PMID 23336684 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT00492960↗

    PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT00620451↗

    PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT00889473↗

    PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT01396213↗

    PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT00362856↗

    PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT00386490↗

    PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT01396213 · retained source version 2017-09-20:7ba139d368702adc6d5b6390c4289e5cdbb7334b55fc7b5bd52909395c9e72f8 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT05747534 · retained source version 2026-08-18:2f77ae5d1d478910bbbe486307fa9ba66477f1edf63b0947b6ab06b6618fadda ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    Larazotide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial (2015) · PMID 25683116 ↗

    Gastroenterology · Official source · Source checked November 15, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026